Compare POET & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POET | TBPH |
|---|---|---|
| Founded | 1972 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 843.0M | 1.0B |
| IPO Year | 2008 | 2013 |
| Metric | POET | TBPH |
|---|---|---|
| Price | $6.83 | $13.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.20 |
| AVG Volume (30 Days) | ★ 5.5M | 588.0K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.88 |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | $2,939.08 | $70.90 |
| Revenue Next Year | $710.17 | N/A |
| P/E Ratio | ★ N/A | $15.77 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.10 | $7.90 |
| 52 Week High | $9.41 | $21.03 |
| Indicator | POET | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 58.24 | 22.66 |
| Support Level | $5.05 | $13.58 |
| Resistance Level | $7.66 | $14.76 |
| Average True Range (ATR) | 0.45 | 0.94 |
| MACD | 0.18 | -0.58 |
| Stochastic Oscillator | 76.00 | 8.27 |
POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).